Our findings indicate a closer association of serum CMW level with ABI than with cystatin C. Furthermore, serum CMW levels were increased with the progression from borderline PAD to PAD, which suggests that serum CMW could be a biomarker for not only assessing the onset of PAD, but also for monitoring the progression of PAD in daily clinical practice. The gene discussed is CST3; the disease is peripheral arterial disease.